Jonathan Dry

Company: Tempus

Job title: Vice President, Scientific Discovery

Seminars:

Trends for ERBB2 and Her2-Targeting Therapies in Real-World Multi-Modal Data 10:00 am

The Tempus platform supports assessment of tumor genetics, transcriptomics, imaging and clinical outcomes across our vast US clinical network Integration of multiple data modalities enables integration of Her2 status in the context of most other clinical biomarkers relevant to breast cancer Transcriptomics can provide a surrogate to expand the clinical utility of Her2 outside of…Read more

day: Day Two